Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + R-CDOP in High-Risk DLBCL
NCT06290817Phase 2
Key facts
- Status
- Recruiting
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Countries
- 1
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Small Molecules
- Drugs
- orelabrutinib
- Conditions
- diffuse large B-cell lymphoma (DLBCL)
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: 2-year central nervous system relapse rate. Started Mar 2023; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Orelabrutinib + R-CDOP
Orelabrutinib 150mg QD + Rituximab, Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone
03
Endpoints
Primary
2-year central nervous system relapse rate
Secondary
Complete Response Rate
Overall Response Rate
Overall Survival
Progression-Free Survival
Occurrence of hematologic and non-hematologic adverse events
Beyond the preview
Go deeper on NCT06290817.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290817.